Skip to main content
SpringerLink
Log in

Trombocytenaggregatieremming of antistolling?acetylsalicylzuur trombocytenaggregatieremmers antistollingsmiddelen hart- en vaatziekten

  • Artikelen
  • Published:
Bijblijven

Samenvatting

Ter secundaire preventie van hart- en vaatziekten na het doormaken van een tia of cva worden onder meer antistollingsmiddelen en trombocytenaggregatieremmers voorgeschreven. Besproken worden acetylsalicylzuur, coumarinederivaten, clopidogrel en dipyridamol, gevolgd door beleidsaanbevelingen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatuur

  • Eriksson SE, Olsson JE. Survival and recurrent strokes in patients with different subtypes of stroke: a fourteen-year follow-up study. Cerebrovasc Dis 2001;12:171-80.

    Article  CAS  PubMed  Google Scholar 

  • Appelros P, Nydevik I, Viiranen M. Poor outcome after first-ever stroke: predictors for death, dependency, and recurrent stroke within the first year. Stroke 2003;34:122-6.

    Article  PubMed  Google Scholar 

  • Hartmann A, Rundek T, Mast H, et al. Mortality and causes of death after first ischemic stroke: the Northern Manhattan stroke study. Neurology 2001;57:2000-5.

    CAS  PubMed  Google Scholar 

  • Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.

    Google Scholar 

  • Johnson ES, Lanes SF, Wentworth CE, et al. A metaregression analysis of the dose-response effect of aspirin on stroke. Arch Intern Med 1999;159:1248-53.

    Article  CAS  PubMed  Google Scholar 

  • The Dutch tia Trial Study Group. A comparison of two doses of aspirin (30 mg versus 283 mg a day) in patients after a transient ischemic attack or a minor ischemic stroke. N Eng J Med 1991;325:1261-6.

    Google Scholar 

  • Algra A. 30 mg acetylsalicylzuur per dag even effectief als 283 mg bij patiënten na een ‘transient ischaemic attack’ of een niet-invaliderend herseninfarct, en met minder bijwerkingen. Ned Tijdschr Geneeskd 1991;135:2273-80.

    Google Scholar 

  • Kalmann R, Nieuwenhuis HK, Groot P de, Gijn J van. Effects of low dosis of aspirin, 10 mg and 30 mg daily, on bleeding time, tromboxane production and 6-keto-PGF1[alpha]-excretion in healthy subjects. Tromb Res 1987;45:355-61.

    Article  Google Scholar 

  • Algra A, Koudstaal PJ, Gijn J van. Secundaire preventie na cerebrale ischemie: monotherapie met acetylsalicylzuur nog steeds de eerste keus? Ned Tijdschr Geneeskd 1998;142:277-80.

    CAS  PubMed  Google Scholar 

  • International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997;349:1569-81.

    Google Scholar 

  • CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20000 patients with acute ischaemic stroke. Lancet 1997;349:1641-9.

    Google Scholar 

  • Chem ZM, Sandercock P, Pan HC, et al. Indications for early aspirin use in acute ischemic stroke. A Regular analysis of 40.000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. Stroke 2000;31:1240-9.

    Google Scholar 

  • Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 1998;129:394-405.

    CAS  PubMed  Google Scholar 

  • CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.

    Google Scholar 

  • Anonymous. Clopidrogrel and ticlopidine. Improvements on aspirin. DTB 1999;37:59-61.

  • Niessen LW, Dippel DWJ, Limburg M. Berekening van kosten na een beroerte en kosteneffectiviteit van ‘stroke-units’ en van secundaire preventie, zoals aanbevolen in de herziene CBO-richtlijn Beroerte. Ned Tijdschr Geneeskd 2000;144:1959-64.

    CAS  PubMed  Google Scholar 

  • Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13.

    Article  CAS  PubMed  Google Scholar 

  • Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.

    Google Scholar 

  • Redman AR, Ryan GJ. Analysis of trials evaluating combinations of acetylsalicylic acid and dipyridamole in the secondary prevention of stroke. Clin Ther 2001;23:1391-408.

    Article  CAS  PubMed  Google Scholar 

  • European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-62.

    Google Scholar 

  • Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492-501.

    CAS  PubMed  Google Scholar 

  • European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with non-rheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995;333:5-10.

    Google Scholar 

  • Smidt P, Arnesen A, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990;323:147-52.

    Article  Google Scholar 

  • The Stroke Prevention In Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997;42:857-65.

    Google Scholar 

  • Gorter JW. Preventieve behandeling van patiënten na niet-invaliderende cerebrale ischemie door vermoedelijk arteriële oorzaak: vergelijkend, gerandomiseerd onderzoek met intensieve antistollingstherapie of behandeling met acetylsalicylzuur. Ned Tijdschr Geneeskd 1998;142:306-12.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. www.bijblijven.bsl.nl

    Tj. Wiersma

Authors
  1. Tj. Wiersma
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Dr. Tj. Wiersma, huisarts, senior wetenschappelijk medewerker Nederlands Huisartsen Genootschap te Utrecht

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wiersma, T. Trombocytenaggregatieremming of antistolling?acetylsalicylzuur trombocytenaggregatieremmers antistollingsmiddelen hart- en vaatziekten . BIJB 20, 40–43 (2004). https://doi.org/10.1007/BF03059754

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03059754

Search

Navigation